Thursday, 15 October 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Earnings callYahoo Finance· November 18, 2025

Navios NMM Earnings Call Transcript

View original at finance.yahoo.com
Navios NMM Earnings Call Transcript Image source: The Motley Fool. Date Tuesday, Nov. 18, 2025 at 8:30 a.m…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • 234 Capesize vessels needed for new iron ore capacity, but only 173 vessels in current order book

    80% confidence
  • Company is laser-focused on business and modernizing fleet

    80% confidence
  • Tanker market outlook is positive over medium term based on low order book, aging fleet, reduced fleet from sanctions

    80% confidence
  • Drybulk market outlook is positive based on steady long-term demand growth and constrained vessel supply

    80% confidence
  • Tariffs not expected to significantly affect tankers/drybulk except steel; reduced container/grain impact expected post US-China trade deal

    80% confidence
  • Geopolitical risk, regional conflict, tariff changes, and evolving trade patterns are unprecedented

    80% confidence
  • Sanctioned tankers total 785 vessels, representing approximately 14% of total capacity removed

    80% confidence
  • Diversification is strength when embedded in risk management culture

    80% confidence
  • EBITDA run rate of approximately €750M over past 4 years

    80% confidence
  • Five years of constant change in operating environment driven by geopolitical events

    80% confidence
  • Company has strong risk management culture, continuously monitoring and assessing risk

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com